Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Trial details
- Registry ID
- NCT06822790
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ARO-APOC3
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaNCT06822790 | Arrowhead Pharmaceuticals | Phase 3 | Active not recruiting | 2028-07Estimated |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaNCT06347003 | Arrowhead Pharmaceuticals | Phase 3 | Completed | 2026-06-12Actual |
| Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaNCT06347133 | Arrowhead Pharmaceuticals | Phase 3 | Completed | 2026-06-01Actual |
| Study of Plozasiran in Adults With Severe HypertriglyceridemiaNCT06347016 | Arrowhead Pharmaceuticals | Phase 3 | Completed | 2026-06-17Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |